Evidence map›Paper›PMID 32154908›Full record

ArticleCancer2020

Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data.

Celestia S Higano, Andrew J Armstrong, Oliver Sartor, Nicholas J Vogelzang, Philip W Kantoff, David G McLeod, Christopher M Pieczonka, David F Penson, Neal D Shore, Jeffrey Vacirca and 11 more

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors.

Celestia S HiganoDivision of Medical Oncology, Departments of Medicine and Urology, University of Washington, Seattle, Washington.
Andrew J ArmstrongDivisions of Medical Oncology and Urology, Duke University Medical Center, Duke Cancer Institute, Duke University, Durham, North Carolina.ORCID 0000-0001-7012-1754
Oliver SartorSection of Hematology and Medical Oncology, Department of Medicine, Tulane Cancer Center and Tulane University School of Medicine, New Orleans, Louisiana.ORCID 0000-0002-8777-7343
Nicholas J VogelzangDivision of Hematology/Oncology, Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada.
Philip W KantoffDepartment of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York.
David G McLeodDepartment of Surgery, Center for Prostate Disease Research, Uniformed Services of Health Sciences, Walter Reed National Military Medical Center, Bethesda, Maryland.
Christopher M PieczonkaAssociated Medical Professionals, Syracuse, New York.
David F PensonDepartments of Urologic Surgery and Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee.
Neal D ShoreDepartment of Urology, Carolina Urologic Research Center, Myrtle Beach, South Carolina.
Jeffrey VacircaNew York Cancer and Blood Specialists, New York, New York.
Raoul S ConcepcionUrology Associates PC, Nashville, Tennessee.
Ronald F TutroneChesapeake Urology, Towson, Maryland.
Luke T NordquistDepartment of Medical Oncology, GU Research Network, Omaha, Nebraska.
David I QuinnDivision of Medical Oncology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California.
Vahan KassabianAdvanced Urology, Atlanta, Georgia.
Mark C ScholzProstate Cancer Research Institute, Marina del Rey, California.
Matt HarmonDendreon Pharmaceuticals LLC, Seattle, Washington.
Robert C TylerDendreon Pharmaceuticals LLC, Seattle, Washington.
Nancy N ChangDendreon Pharmaceuticals LLC, Seattle, Washington.
Hong TangDendreon Pharmaceuticals LLC, Seattle, Washington.
Matthew R CooperbergDepartments of Urology and Epidemiology & Biostatistics, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Prostatic Neoplasms, Castration-ResistantHumansMaleRegistriesTissue Extractssipuleucel-TTissue Extracts

Identifiers

PMID32154908
PMCPMC7935468

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.